Gene therapy for dopamine replacement.

Summary, in English

Dopamine replacement for Parkinson's disease (PD) have seen three major iterations of improvements since the introduction of l-3,4-dihydroxyphenylalanine (l-DOPA) pharmacotherapy: dopamine receptor agonists, ex vivo gene transfer for cell transplantation and most recently in vivo gene therapy. In this chapter, we describe the principles behind viral vector-mediated enzyme replacement in PD. We focus on the enzymes involved in the dopamine synthesis and their internal regulation, the early experimental work on gene therapy using different viral vector types and selection of transgenes, and finally discuss the recently completed early phase clinical trials in PD patients.

• Författare: Tomas Björklund; Erik Cederfjäll; Deniz Kirik
• Avdelning/ar: Molekylär neuromodulering; Brain Repair and Imaging in Neural Systems (BRAINS); MultiPark: Multidisciplinary research focused on Parkinson´s disease; eSSENCE: The e-Science Collaboration
• Publiceringsår: 2010
• Språk: Engelska
• Sidor: 221-235
• Publikation/Tidskrift/Serie: Progress in Brain Research
• Volym: 184
• Länkar: http://www.ncbi.nlm.nih.gov/pubmed/20887878?dopt=Abstract; http://dx.doi.org/10.1016/S0079-6123(10)84012-9
• Dokumenttyp: Artikel i tidskrift
• Förlag: Elsevier
• Ämne: Neurosciences
• Status: Published
• Forskningsgrupp: Molecular Neuromodulation; Brain Repair and Imaging in Neural Systems (BRAINS)
• ISBN/ISSN/Övrigt: ISSN: 1875-7855